In vitro activity of aminoglycosides, clofazimine, D-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates

Journal of Microbiology, Immunology and Infection

Volumn 51, Issue 5, 2018, Pages 636-643

  Huang, Chen Cheng ^a   Wu, Ming Feng ^b,c   Chen, Hui Chen ^b   Huang, Wei Chang ^b,d  

^a Taichung Hospital   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d JEN TEH JUNIOR COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Aminoglycosides; Clofazimine; In vitro activity; Mycobacterium avium complex

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DAPSONE; ISEPAMICIN; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; STREPTOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; GENTAMICIN; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENTIATION; IN VITRO STUDY; MIC50; MIC90; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; ATYPICAL MYCOBACTERIOSIS; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; SPUTUM;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; DRUG SYNERGISM; FLUOROQUINOLONES; GENTAMICINS; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; SPUTUM; STREPTOMYCIN;

EID: 85021967619     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.05.001     Document Type: Article

References (41)

1. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (2007), 367–416.
2. Kobashi, Y., Matsushima, T., Oka, M., A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 101 (2007), 130–138.
3. Huang, J.H., Kao, P.N., Adi, V., Ruoss, S.J., Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without pre-existing lung disease: diagnostic and management limitations. Chest 115 (1999), 1033–1040.
4. Field, S.K., Fisher, D., Cowie, R.L., Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 126 (2004), 566–581.
5. Barrett, M.S., Jones, R.N., Erwin, M.E., Koontz, F.P., CI-960 (PD127391 or AM-1091), sparfloxacin, WIN 57273, and isepamicin activity against clinical isolates of Mycobacterium avium-intracellularae complex, M. chelonae, and M. fortuitum. Diagn Microbiol Infect Dis 15 (1992), 169–171.
6. Heifets, L., MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven anti-tuberculosis drugs. Antimicrob Agents Chemother 32 (1988), 1131–1136.
7. Heifets, L., Lindholm-Levy, P., Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother 33 (1989), 1298–1301.
8. Rastogi, N., Goh, K.S., Labrousse, V., Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms. Eur J Clin Microbiol Infect Dis 12 (1993), 954–958.
9. Rastogi, N., Bauriaud, R.M., Bourgoin, A., Carbonnelle, B., Chippaux, C., Gevaudan, M.J., et al. French multicenter study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex. Antimicrob Agents Chemother 39 (1995), 638–644.
10. Tomioka, H., Sato, K., Saito, H., In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs. Kekkaku 66 (1991), 489–492.
11. Venugopal, D., Kumar, S., Isa, M., Bose, M., Drug resistance profile of human Mycobacterium avium complex strains from India. Indian J Med Microbiol 25 (2007), 115–120.
12. Telenti, A., Marchesi, F., Balz, M., Bally, F., Böttger, E.C., Bodmer, T., Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 31 (1993), 175–178.
13. Kim, B.J., Hong, S.K., Lee, K.H., Yun, Y.J., Kim, E.C., Park, Y.G., et al. Differential identification of Mycobacterium tuberculosis complex and nontuberculous mycobacteria by duplex PCR assay using the RNA polymerase gene (rpoB). J Clin Microbiol 42 (2004), 1308–1312.
14. Wayne, P.A., Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes. 2011, Clinical and Laboratory Standards Institute Approved standard. CLSI document Second Edition, M24-A2.
15. Wallace, R.J. Jr., Nash, D.R., Steele, L.C., Steingrube, V., Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 24 (1986), 976–981.
16. Brown, B.A., Wallace, R.J. Jr., Onyi, G.O., Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 36 (1992), 1987–1990.
17. Abate, G., Miorner, H., Ahmed, O., Hoffner, S.E., Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 2 (1998), 580–584.
18. De Logu, A., Onnis, V., Saddi, B., Congiu, C., Schivo, M.L., Cocco, M.T., Activity of a new class of isonicotinoyl hydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis. J Antimicrob Chemother 49 (2002), 275–282.
19. Odds, F.C., Synergy, antagonism, and what the checkerboard puts between them. J Antimicrob Chemother, 52, 2003, 1.
20. Olivier, K.N., Shaw, P.A., Glaser, T.S., Bhattacharyya, D., Fleshner, M., Brewer, C.C., et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 11 (2014), 30–35.
21. Blum, D., An overview of the safety of isepamicin in adults. J Chemother 7:Suppl. 2 (1995), 87–93.
22. Tod, M., Padoin, C., Petitjean, O., Clinical pharmacokinetics and pharmacodynamics of isepamicin. Clin Pharmacokinet 38 (2000), 205–223.
23. Suzuki, A., Nishimura, T., Ohtawa, S., Mikami, J., Kurashima, A., Saito, M., et al. Clinical efficacy of kanamycin for Mycobacterium avium complex disease. Yakugaku Zasshi 128 (2008), 451–460.
24. Wirmer, J., Westhof, E., Molecular contacts between antibiotics and the 30S ribosomal particle. Methods Enzymol 415 (2006), 180–202.
25. Brown-Elliott, B.A., Nash, K.A., Wallace, R.J. Jr., Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 25 (2012), 545–582.
26. Lambert, M.P., Neuhaus, F.C., Mechanism of d-cycloserine action: alanine racemase from Escherichia coli W. J Bacteriol 110 (1972), 978–987.
27. Prosser, G.A., de Carvalho, L.P.S., Metabolomics reveal d-Alanine:d-Alanine ligase as the target of d-cycloserine in Mycobacterium tuberculosis. ACS Med Chem Lett 4 (2013), 1233–1237.
28. Desjardins, C.A., Cohen, K.A., Munsamy, V., Abeel, T., Maharaj, K., Walker, B.J., et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet 48:5 (2016 May), 544–551.
29. Field, S.K., Cowie, R.L., Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 124 (2003), 1482–1486.
30. Roussel, G., Igual, J., Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome. GETIM. Groupe d'Etude et de Traitement des Infections à Mycobactéries. Int J Tuberc Lung Dis 2 (1998), 462–470.
31. Cholo, M.C., Mothiba, M.T., Fourie, B., Anderson, R., Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline. J Antimicrob Chemother 72:2 (2017 Feb), 338–353.
32. Somoskovi, A., Bruderer, V., Hömke, R., Bloemberg, G.V., Böttger, E.C., A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 45 (2015), 554–557.
33. Hartkoorn, R.C., Uplekar, S., Cole, S.T., Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 2979–2981.
34. Zhang, S., Chen, J., Cui, P., Shi, W., Zhang, W., Zhang, Y., Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 70 (2015), 2507–2510.
35. Shen, G.H., Wu, B.D., Wu, K.M., Chen, J.H., In vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 51 (2007), 1849–1851.
36. Alangaden, G.J., Kreiswirth, B.N., Aouad, A., Khetarpal, M., Igno, F.R., Moghazeh, S.L., et al. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42 (1998), 1295–1297.
37. Jugheli, L., Bzekalava, N., de Rijk, P., Fissette, K., Portaels, F., Rigouts, L., High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother 53 (2009), 5064–5068.
38. Shen, G.H., Wu, B.D., Hu, S.T., Lin, C.F., Wu, K.M., Chen, J.H., High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 35 (2010), 400–404.
39. van Ingen, J., Totten, S.E., Helstrom, N.K., Heifets, L.B., Boeree, M.J., Daley, C.L., In vitro synergy between clofazimine and amikacin in treatment of non-tuberculous mycobacterial disease. Antimicrob Agents Chemother 56 (2012), 6324–6327.
40. da Silva Telles, M.A., Chimara, E., Ferrazoli, L., Riley, L.W., Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates. J Med Microbiol 54 (2005), 975–979.
41. van Ingen, J., Hoefsloot, W., Mouton, J.W., Boeree, M.J., van Soolingen, D., Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. Int J Antimicrob Agents 42 (2013), 80–82.